Our database-based survival analysis results indicated that ccRCC patients with high LAMP1 expression had significantly longer overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) than those with low LAMP1 expression. This evidence concerns the gene LAMP1 and nonpapillary renal cell carcinoma.